|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This comparison showed that immunohistochemical bio-profiles select those cases not associated with high risk-of-recurrence of disease (luminal-A/B and luminal A/B Bcl2) and those that are instead at high risk and therefore worthy of chemotherapy (luminal-B ki67 and luminal-B Bcl2/Ki67), strongly suggesting to only submit PGR-positive/Bcl2-Ki67 altered cases to Oncotype Dx, thus reducing the number of cases to be tested.
|
31158261 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
microRNA-21 was up-regulated in HER2 positive and Basal-like breast cancer types, while microRNA-206 was up-regulated in Luminal A and B types of breast cancer. microRNA-21 expression negatively correlated with the level of ER and PR but positively correlated with HER2 expression and tumor malignancy, while microRNA-206 showed the opposite trend.
|
31276668 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of the current study were (1) to analyze invasive breast carcinomas using standardized 4-IHC and quantitative image analysis and (2) to compare the results obtained in the classification of biological subtypes using current Ki67 and PR threshold values proposed by different authors to sub-classifying the luminal A-like and the luminal B-like (HER2-negative) subtypes.
|
28825136 |
2018 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients were divided into four groups based on the tumor molecular subtype: luminal A (Estrogen Receptor [ER]/Progesterone Receptor [PR] positive, human epithelial growth factor receptor-2 [HER2] negative), luminal B (ER/PR positive, HER2 Positive), HER2 (HER2 positive and ER/PR negative), and Triple negative (TNBC).
|
30596408 |
2018 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We classified breast cancer cases into four subtypes using information on tumor marker expression such as estrogen receptor (ER), progesterone receptor (PR), and Cerb2 receptor (HER2); luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2-overexpressing (ER-, PR-, and HER2+), and triple-negative (ER-, PR-, and HER2-).
|
28957821 |
2018 |
|
Luminal A Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lysyl oxidase positivity was associated with progesterone receptor negativity ( p = 0.001), and monoamine oxidase A positivity was associated with human epidermal growth factor receptor-2 negativity ( p = 0.003) and the luminal A subtype ( p = 0.003).
|
29775160 |
2018 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study utilized the human mammary carcinoma-derived, ER<sup>+</sup>/PR<sup>+</sup>/HER-2<sup>-</sup> MCF-7 cell line as a model of the Luminal A subtype of breast cancer to examine the growth inhibitory effect of the Chinese nutritional herb <i>Epimedium grandiflorum</i> (EG) and determine the mechanisms underlying this effect.
|
28454423 |
2017 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors were classified into molecular subtypes: luminal A (ER-positive and/or progesterone receptor (PR)-positive, human epidermal growth factor receptor type 2 (HER2) -negative, proliferation marker Ki-67 < 20 and low grade (I)) and luminal B (ER-positive and/or PR-positive, HER2-positive or HER2-negative with high Ki-67 ≥ 20 and higher grade (II or III)).
|
29284425 |
2017 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
YAP is mainly localized within the tumor cell nuclei, and its expression was associated with the PR status and luminal A subtype.
|
28899737 |
2017 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comprehensive transcriptional profiling studies have revealed at least 4 principal subtypes that, in practice, are often distinguished by immunohistochemical staining of the estrogen receptor (ER), progesterone receptor (PR), and HER2, along with a determination of histologic grade or Ki-67 staining: luminal A (ER+/HER2-/grade 1 or 2), luminal B (ER+/HER2-/grade 3), HER2 enriched (any HER2+ tumor), and basal like (ER-/PR-/HER2-).
|
26617205 |
2016 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Determination of PgR expression combined with that of Ki-67 could thus improve the accuracy of IHC-based classification of luminal A and luminal B breast cancer, especially for postmenopausal women.
|
25600243 |
2015 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (Her2/neu) immunostaining was semi-quantitatively assessed to define molecular subtypes of luminal A and B, HER-2 and triple negative (basal- like) in BC paraffin embedded sections from 115 Saudi female patients diagnosed between 2005 to 2015 at the Department of Pathology, King Fahd Hospital, Almadinah, Saudi Arabia.
|
26625804 |
2015 |
|
Luminal A Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine the utility of Ki67 in assignment of immunohistochemically molecular subtypes, cases were assigned into Luminal A (ER-positive, HER2-negative, Ki67 ≤14%), Luminal B (ER-positive, HER2-negative, Ki67 >14%) and triple negative (ER/PR-negative and HER2-negative, any Ki67).
|
24403187 |
2014 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinicopathologic comparisons among luminal A and B subtypes consistently identified higher rates of PR positivity, human epidermal growth factor receptor 2 (HER2) negativity, and histologic grade 1 in luminal A tumors.
|
23233704 |
2013 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently it has been shown that immunohistochemistry (IHC) markers including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2), can divide tumors to main subtypes: luminal A (ER+; PR+/-; HER-2-), luminal B (ER+;PR+/-; HER-2+), basal-like (ER-;PR-;HER2-) and Her2+ (ER-; PR-; HER-2+).
|
23098526 |
2012 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The invasive breast carcinomas were classified using semiquantitative immunohistochemical results for estrogen receptor (ER), progesterone receptor, (PR), and HER2 into following classes: Luminal A (strong ER+, HER2 negative), Luminal B (weak to moderate ER/PR+, HER2 negative), Triple Negative (TN; ER/PR negative, HER2 negative), ERBB2 (ER/PR negative, HER2 positive), Luminal A-HER2 Hybrid (strong ER+, HER2 positive), Luminal B-HER2 Hybrid (weak to moderate ER/PR+, HER2 positive).
|
19801938 |
2010 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancers were categorized as luminal A (ER-alpha+ and/or PR+ and HER2-); luminal B (ER-alpha+ and/or PR+ and HER2+); HER2 (ER-alpha- and PR- and HER2+); and basal-like (ER-alpha-, PR-, HER2- and EGFR or cytokeratin 5/6+).
|
19898422 |
2010 |